Results 151 to 160 of about 87,754 (311)

Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival [PDF]

, 2017
Gutmann, David H, Hambardzumyan, Dolores, Ma, Yu, Pan, Yuan, Smithson, Laura J   +4 more
core   +2 more sources

Intussuscepção intestinal decorrente de tumor de estroma gastrointestinal (GIST) em paciente com neurofibromatose tipo 1 / Intestinal intusception arising from gastrointestinal stroma tumor (GIST) in patient with neurofibromatosis type 1

, 2020
Laila de Castro Tayer, Emanuely Sampaio Clemente dos Reis, Larissa de Castro Tayer, Larissa Morais Souza, Vanessa Tayer Nogueira, Flávia Gomes Fialho, Omar Tayer   +6 more
openalex   +1 more source

Usefulness of 18F-FDG-PET/CT in Evaluating a Brainstem Glioma in an Adult Patient with Neurofibromatosis Type 1 [PDF]

, 2013
Giorgio Treglia, Barbara Muoio, Annemilia del Ciello, Francesco Bertagna   +3 more
openalex   +1 more source

Clinicopathological Characteristics and Outcomes of Genitourinary Rhabdomyosarcoma in Two Girls

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Rhabdomyosarcoma (RMS) is a soft tissue neoplasm accounting for about 8% of solid tumors in children. There are mainly four histologic subtypes of RMS: embryonal, alveolar, spindle cell/sclerosing, and pleomorphic. The genitourinary tract is the second most affected primary site of RMS. Genitourinary RMS is more common in young boys than girls.
George Evele, Francine Kouya, George Ngock, Richard Bardin   +3 more
wiley   +1 more source

Corpus callosum tumor as the presenting symptom of neurofibromatosis type 1 in a patient and literature review [PDF]

, 2012
Introducción. La neurofibromatosis tipo 1 (NF1) es uno de los síndromes neurocutáneos más frecuentes y puede asociarse a tumores intracraneales en cualquier localización, pero excepcionalmente en el cuerpo calloso. Objetivos.
Pascual-Castroviejo, Ignacio, Pascual-Pascual, S. I., Velázquez-Fragua, Ramón, Viaño, Juan   +3 more
core   +1 more source

Clinicopathological and Immunohistochemistry Study of a Long Survivor of Giant Cell Glioblastoma in a Patient With Neurofibromatosis 1: Case Report [PDF]

, 2023
Noora Al-romaihi, Mohammed Awadh, Mohammed Albalooshi, Mohammed Ahmed, Abdulla Darwish   +4 more
openalex   +1 more source

Analysis of Real‐World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1340-1349, May 2026.
In the field of rare diseases—where traditional clinical trials are often impractical—real‐world data (RWD) have emerged as a scientifically valid alternative to support regulatory decision making. This study systematically evaluates the utilization of RWD in orphan drug approvals by the FDA Center for Drug Evaluation and Research (CDER) over the past ...
Minji Kim, Eunjin Hong
wiley   +1 more source

Multiple glomus tumors and segmental neurofibromatosis: there are no coincidences [PDF]

, 2011
Segmental neurofibromatosis is a rare subtype of neurofibromatosis type 1 (NF1). Glomus tumors are uncommon benign tumors.
Cabral, R, Santiago, F, Tellechea, O
core   +1 more source

Yield of Whole Genome Sequencing for Pathogenic Single Nucleotide Variants in Congenital Heart Disease: A Systematic Review and Meta‐Analysis

Prenatal Diagnosis, Volume 46, Issue 5-6, Page 780-818, May 2026.
ABSTRACT Objective This systematic review and meta‐analysis aimed to assess the diagnostic yield of pathogenic or likely pathogenic (P/LP) single nucleotide variants (SNVs) using whole genome sequencing (WGS) in congenital heart disease (CHD). Methods A systematic search of three databases (2000–2024) was conducted, and two reviewers independently ...
Hiba J. Mustafa, Parisa Najjariasl, Faezeh Aghajani, Enaja V. Sambatur, Andrew Rodenbarger, Stephanie Guseh, Amy E. Roberts, Alireza A. Shamshirsaz   +7 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source